Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial.
LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company’s migration from proof of concept to the clinical application of PRINT technology.
“The primary objective of this trial is to evaluate the safety and immune response in healthy young adults and adults over 65, a group that often responds sub-optimally to standard flu vaccines,” said Frank Malinoski, Chief Medical Officer at Liquidia. “We believe that this vaccine, using proprietary PRINT particles, has the potential to offer a robust immune response and an improved safety and tolerability profile as compared to alternative approaches to delivering the influenza vaccine.”
LIQ-001 is the most advanced product candidate in a robust portfolio of novel vaccine carriers being developed by Liquidia. Like LIQ-001, follow-on vaccine products will leverage the unique features of the PRINT technology in order to rapidly advance clinical products that have the potential to offer an enhanced immune response against a range of diseases.
“Advancing our first vaccine product from concept, through GMP production, to a clinical candidate in just over 18 months demonstrates the power and simplicity of the vaccines technology platform here at Liquidia,” said Neal Fowler, Chief Executive Officer at Liquidia. “We believe our particle engineering and manufacturing control are unprecedented and provide us with a unique opportunity to improve the prevention and treatment of diseases for patients worldwide.”
Source: http://www.liquidia.com/